]>
IRCT2014020114333N17 IRCT 2014-02-12 Kermanshah University of Medical Sciences Anti-Mullerian hormone levels of uterine artery embolization in the treatment of patients suffering Myomectomy and uterine leiomyoma Comparison of anti-Mullerian hormone level in two treatment methods, myomectomy and uterine artery embolization, in patients with uterine fibroids 2013-09-11 anticipated 50 Complete https://irct.ir/trial/13953 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. N/A utrine fibroids and bleeding. Intervention 1: In the second treatment group, patients will be treated through myomectomy. Then anti-Mullerian hormone and hemoglobin levels will be checked 6 months after surgery. Intervention 2: In the first treatment group, patients will be treated through uterine artery embolization. Then anti-Mullerian hormone and hemoglobin levels will be checked 6 months after surgery.
public
scientific Dr.farahnaz Keshavrzi
Emam Reza Hospital,Razi Boulevard,Sorkhleje
Kermanshah Iran (Islamic Republic of) +98 83 1427 6309 fnkeshavarzi@yahoo.com Kermanshah University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: age 25-40 years; having debilitating complaints such as severe bleeding due to myoma, uterine enlargement up to 16 weeks pregnancy, anemia and pressure on the pelvic organs of patients which candidates her for myomectomy. Exclusion criteria: probability of pelvic malignancies, ovarian pathologies, pelvic infections; desiring fertility, contrast sensitivity, renal disorders, and systemic autoimmune disorders. 25 years 40 years Female N85.8 Other specified noninflammatory disorders of uterus Treatment - Surgery Treatment - Surgery In the second treatment group, patients will be treated through myomectomy. Then anti-Mullerian hormone and hemoglobin levels will be checked 6 months after surgery. In the first treatment group, patients will be treated through uterine artery embolization. Then anti-Mullerian hormone and hemoglobin levels will be checked 6 months after surgery. Duration of returning to work. Timepoint: 6 months after discharge. Method of measurement: Asking the patient. Anti-Mullerian hormone level. Timepoint: Baseline and 6 months after surgery. Method of measurement: Measurement in the laboratory. Patients’ complaints (hot flush, bleeding, pelvic pain and pressure, urinary problems, etc.). Timepoint: 6 months after intervention. Method of measurement: Asking the patient. Pain level. Timepoint: One week after intervention. Method of measurement: Asking the patient. Duration of hospitalization. Timepoint: Discharge date. Method of measurement: Based on patient records. Cost of treatment. Timepoint: Discharge date. Method of measurement: Based on patient records. Kermanshah University of Medical Sciences Approved 2013-09-11 Kermanshah University of Medical Sciences Building No.2, Shahid Beheshti, Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences Kermanshah Iran (Islamic Republic of)